Tag: Rivaroxaban

Virtual ACC: Combining aspirin with rivaroxaban provides greater absolute risk reduction in diabetes

In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative...

Virtual ACC: Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularisation

Treatment with aspirin plus rivaroxaban following lower extremity revascularisation in patients ...

Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD and PAD patients

The National Institute for Health and Care Excellence (NICE) has published the final appraisal deter...
xarelto rivaroxaban

Rivaroxaban recommended by NICE for peripheral and coronary artery disease patients

The National Institute for Health and Care Excellence (NICE) in the UK has published a positive draf...

Rivaroxaban gets FDA approval for treatment in CAD or PAD

Rivaroxaban, brand name Xarelto (Janssen), has received approval by the US Food and Drug Adminis...

Bayer announces new licensed indication for use of Xarelto in patients with coronary artery disease

Xarelto, co-administered with aspirin, is indicated in the EU for the prevention of atherothromb...

Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary artery disease

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and myocardial infarction in patients with coronary artery disease

The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–...

European Medicines Agency issues positive opinion for rivaroxaban

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

COMPASS study of rivaroxaban to end early for efficacy

The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Bayer) fo...

AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients with atrial fibrillation

Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily...